Rezolute Q3 net loss narrows as R&D expenses fall

Rezolute

12/05/2026 21:24

Overview

US rare disease drug developer's fiscal Q3 net loss narrowed yr/yr

R&D expenses fell due to lower manufacturing and clinical trial costs

Company advanced clinical programs for congenital and tumor hyperinsulinism

Outlook

Rezolute expects an update on its congenital HI program in the second half of 2026

Topline results from tumor HI Phase 3 trial expected in the second half of 2026

Result Drivers

LOWER R&D COSTS - Co said decrease in R&D expenses was mainly due to reduced manufacturing costs for ersodetug and lower clinical trial activity

HIGHER ADMIN EXPENSES - Co attributed increase in G&A expenses to higher employee-related stock-based compensation, partially offset by lower professional fees

CLINICAL PROGRAM PROGRESS - Co advanced clinical programs for congenital and tumor HI, including expanded analyses and ongoing studies

Company press release: ID:nGNX5W73fW

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.16
Q3 Net Income
-$16.17 mln
Q3 Income From Operations
-$17.37 mln
Q3 Operating Expenses
$17.37 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Rezolute Inc is $5.00, about 57.7% above its May 11 closing price of $3.17

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)